Global Hyperlipidemia Market Size study, By Type (Familial, Acquired), By Treatment (Statins, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, Combination, Others), By Distribution Channel (Hospital Pharmacy, Retail Phar

Global Hyperlipidemia Market Size study, By Type (Familial, Acquired), By Treatment (Statins, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, Combination, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), and Regional Forecasts 2022-2028

Global Hyperlipidemia Market is valued at approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2028. Hyperlipidemia is also known as high cholesterol or dyslipidemia. It is a condition there are high levels of fat particles (lipids) present in the blood. The rising prevalence of hyperlipidemia, increasing investment in healthcare infrastructure, and growing number of geriatric populations are the primary factors fostering the market demand across the globe. For instance, as per the World Health Organization (WHO), the global population aged 60 years and above is expected to rise from 605 million in 2000 to 2 billion by the year 2050. Consequentially, the increasing aged population is more prone to get affected by a variety of diseases, which is surging the market demand across the globe. However, the high cost associated with the treatment and shortage of skilled professionals impede the growth of the market over the forecast period of 2022-2028. Also, an increase in the number of research and development activities and rising drug approvals and launches are anticipated to act as catalyzing factors for the market demand during the forecast period.

The key regions considered for the global Hyperlipidemia Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the increasing incidences of hyperlipidemia, along with rising technological developments. Whereas, Asia-Pacific is anticipated to exhibit the highest CAGR over the forecast period 2022-2028. Factors such as the growing expenditure on healthcare facilities, as well as the increasing geriatric population, would create lucrative growth prospects for the Hyperlipidemia Market across the Asia-Pacific region.

Major market players included in this report are:
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.
GlaxoSmithKline plc
Novartis AG
Johnson & Johnson Private Limited
Sun Pharmaceutical Industries Ltd.
Merck & Co., Inc.
Bristol-Myers Squibb Company
Eli Lilly and Company
Regeneron Pharmaceuticals Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:
Familial
Acquired
By Treatment:
Statins
Bile Acid Sequestrants
Cholesterol Absorption Inhibitors
Fibric Acid Derivatives
Combination
Others
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Hyperlipidemia Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors


Companies Mentioned

Teva Pharmaceutical Industries Ltd.
Pfizer Inc.
GlaxoSmithKline plc
Novartis AG
Johnson & Johnson Private Limited
Sun Pharmaceutical Industries Ltd.
Merck & Co., Inc.
Bristol-Myers Squibb Company
Eli Lilly and Company
Regeneron Pharmaceuticals Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions. Show more